原发性胆汁性胆管炎药物治疗新进展*

doi:10.3969/j.issn.1672-5069.2021.06.003

实用肝脏病杂志 ›› 2021, Vol. 24 ›› Issue (6): 772-775.doi: 10.3969/j.issn.1672-5069.2021.06.003

原发性胆汁性胆管炎药物治疗新进展^*

吕艳, 杨益大

310003 杭州市浙江大学医学院附属第一医院传染病诊治国家重点实验室/国家感染性疾病临床医学研究中心/感染性疾病诊治协同创新中心

收稿日期:2021-09-01 出版日期:2021-11-10 发布日期:2021-11-15
通讯作者: 杨益大,E-mail:yidayang65@zju.edu.cn
作者简介:吕艳,女,24岁,硕士研究生,住院医师。主要从事慢性乙型肝炎抗病毒治疗研究。E-mail:ly0406@zju.edu.cn
基金资助:
^*国家“十三五”科技重大专项-免疫调节/抗病毒联合治疗新方案提高慢性乙型肝炎临床治愈率及其对远期转归的影响(编号:2017ZX10202202)

Medical management of patients with primary biliary cholangitis

Lyu Yan, Yang Yida

Department of Infectious Diseases, First Affiliated Hospital, Zhejiang University, Hangzhou 310003, Zhejiang Province, China

Received:2021-09-01 Online:2021-11-10 Published:2021-11-15

摘要/Abstract

关键词: 原发性胆汁性胆管炎, 胆汁淤积, 熊去氧胆酸, 奥贝胆酸

Key words: Primary biliary cholangitis, Treatment, Progress

吕艳, 杨益大. 原发性胆汁性胆管炎药物治疗新进展^*[J]. 实用肝脏病杂志, 2021, 24(6): 772-775.

Lyu Yan, Yang Yida. Medical management of patients with primary biliary cholangitis[J]. Journal of Practical Hepatology, 2021, 24(6): 772-775.

[1] 中华医学会肝病学分会、消化病学分会、感染病学分会.胆汁淤积性肝病诊断和治疗共识(2015).实用肝脏病杂志,2016,19(6):Ⅰ-ⅩⅠ.
[2] Chung SW, Lee JH, Kim MA. Additional fibrate treatment in UDCA-refractory PBC patients. Liver Int, 2019, 39(9): 1776-1785.
[3] Erlinger S. Obeticholic acid in primary biliary cholangitis. Clin Res Hepatol Gastroenterol, 2017, 41(1): 3-5.
[4] Joyce SA, Gahhan CG. Disease-associated changes in bile acid profiles and links to altered gut microbiota. Dig Dis, 2017, 35(3):169-177.
[5] Lindor KD,Bowlus CL,Boyer J,et al. Primary biliary cholangitis: 2018 practice guidance from the American asociation for the study of liver diseases. Hepatology, 2019,69(1):394-419.
[6] Hirschfield GM,Beuers U,Corpechot C,et al. EASL clinical practice guidelines:the diagnosis and management of patients with primary biliary cholangitis.J Hepatol,2017,67(1): 145-172.
[7] Lazaridis KN, Gores GJ, Lindor KD. 2001. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders.' J Hepatol, 2015,35:134-146.
[8] Beuers H. Druginsight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.Nat Clin Pract Gastroenterol Hepatol,2006, 3:318-328.
[9] Arab JP, Cabrera D, Arrese M. Bile acids in cholestasis and its treatment.Ann Hepatol, 2017,16(Suppl 1):53-57.
[10] Fickert P, Hirschfield GM, Denk G, et al. non-Ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol, 2017,67:549-558.
[11] Pellicciari R, Fiorucci S,Camaioni E, et al. 6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem, 2002, 45:3569-3572.
[12] Ali AH, Lindor KD. Obeticholic acid for the treatment of primary biliary cholangitis .Expert Opin Pharmacother, 2016, 17(13): 1809-1815.
[13] Bowlus CL, Pockros PJ,Kremer AE, et al. Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis .Clin Gastroenterol Hepatol,2020,18(5): 1170-1178.
[14] Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and in adequate response to ursodeoxycholic acid. Gastroenterology,2015,148:751-761.
[15] Michael T, Aliya G, Bilal H, et al. The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis . Hepatology,2019, 70 (3): 788-801.
[16] Carey EJ,Ali AH,Lindor KD. Primary biliary cirhosis. Lancet,2015,386(10003):1565-1575.
[17] Mayo MJ, Wigg AJ, Roberts SK, et al. NGM282, a novel variant of FGF-19, demonstrates biologic activity in primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid: results of a phase 2 multicenter, randomized, double blinded, placebo controlled trial. Hepatology (Baltimore, MD), 2015,62: 263-264.
[18] Dubois V,Eeckhoute J,Lefebvre P, al al. Distinct Buomplementary contributions of PPAR isotypes to energy homeostasis. J Clin, Investig,2017,127:1202-1214.
[19] Corpechot C, Chazouilleres O, Rousseau A, et al. A placebo- controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med, 2018,378:2171-2181.
[20] Corpechot C, Chazouilleres O, Rousseau A, et al. A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso). J Hepatol,2017,66:S89.
[21] Jones D, Boudes PF, Swain MG, et al. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol, 2017, 2:716-726.
[22] Hgade VS, Kendrick SF, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet, 2017, 389(10074): 1114-1123.
[23] Al-Dury S, Wahlstrom A, Wahlin S, et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis.Sci Rep,2018, 8(1): 6658.
[24] Hirschfield GM, Gershwin ME,Strauss R, et al. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study. Hepatology,2017, 64:189-99.
[25] Bowlus CL,Yang GX,Liu CH, et al. Therapeutic trials of biologics in primary biliary cholangitis: an open label study of abatacept and review of the literature. J Autoimmun,2019, 101:26-34.
[26] Wagner M, Fickert P. Drug therapies for chronic cholestatic liver diseases. Annu Rev Pharmacol Toxicol, 2020,60:503-527.
[27] Muir A, Goodman Z, Levy C, et al. Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial. J Hepatol,2017,66:S73.
[28] Zhou J, Huang N, Guo Y, et al. Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis. Acta Pharm Sin B, 2019,9(3):526-536.

原发性胆汁性胆管炎药物治疗新进展^*

Medical management of patients with primary biliary cholangitis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李衍强, 石慧, 王文珊, 林学贤, 王英运. 原发性胆汁性胆管炎患者血浆细胞毒性T淋巴细胞相关蛋白4基因多态性分析[J]. 实用肝脏病杂志, 2021, 24(6): 831-834.
[2]	王绮夏, 马雄. 自身免疫性肝病精准诊治与临床转化研究的思考^*[J]. 实用肝脏病杂志, 2021, 24(4): 457-459.
[3]	张鑫赫, 田昊宇, 李异玲. 原发性胆汁性胆管炎治疗现状[J]. 实用肝脏病杂志, 2021, 24(3): 453-456.
[4]	郭丽, 宋元宗. Alagille综合征患儿临床治疗管理[J]. 实用肝脏病杂志, 2021, 24(2): 160-163.
[5]	聂柳, 彭罕鸣, 廖东亮. 泼尼松和硫唑嘌呤联合熊去氧胆酸治疗自身免疫性肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(2): 224-227.
[6]	蔡宇, 王孟春, 邱新平, 张宁宁, 刘丽莉, 吴博, 杨奇. 复方甘草酸苷联合丁二磺酸腺苷蛋氨酸治疗酒精性肝炎伴胆汁淤积患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 71-74.
[7]	张健荣, 顾尔莉, 王忠成, 施亚军. 自身免疫性肝炎、原发性胆汁性胆管炎及其重叠综合征患者临床特征比较^*[J]. 实用肝脏病杂志, 2020, 23(6): 829-832.
[8]	何胜夫, 汪余勤. 胆汁酸在胆汁淤积性肝损伤发病中的作用研究进展[J]. 实用肝脏病杂志, 2020, 23(6): 919-922.
[9]	邢晓燕, 黄良苗, 符爱仙, 李兴钦, 韩向阳. 茵栀黄联合腺苷蛋氨酸治疗妊娠期肝内胆汁淤积症患者疗效观察及其对母婴结局的影响[J]. 实用肝脏病杂志, 2020, 23(5): 670-673.
[10]	杨涓. 茵陈四苓颗粒对胆汁淤积性肝炎大鼠肝功能损害的改善作用及其机制研究^*[J]. 实用肝脏病杂志, 2020, 23(4): 476-479.
[11]	李文渊, 叶超, 李磊, 方芳, 陈思, 王陆军, 张开光. 原发性胆汁性胆管炎患者血清自身抗体和临床特征分析^*[J]. 实用肝脏病杂志, 2020, 23(4): 516-519.
[12]	黄丽华, 杨正兵, 谭礼让. 熊去氧胆酸联合非诺贝特治疗PBC患者血清TGF-β、IFN-γ和IL-10水平变化^*[J]. 实用肝脏病杂志, 2020, 23(4): 520-523.
[13]	齐敬聪, 邢文静, 杜洋, 高辰玮. 熊去氧胆酸联合微生态制剂治疗原发性胆汁性胆管炎患者对肠道菌群的影响^*[J]. 实用肝脏病杂志, 2020, 23(4): 524-527.
[14]	贾娇, 王芳, 张波, 武琼. 熊去氧胆酸联合骨化三醇治疗原发性胆汁性肝硬化患者疗效和外周血T淋巴细胞亚群的变化^*[J]. 实用肝脏病杂志, 2020, 23(2): 240-243.
[15]	周晓旭, 张华杰, 商志娟. 速度向量成像技术定量参数评估妊娠期肝内胆汁淤积症孕妇胎儿心功能研究^*[J]. 实用肝脏病杂志, 2020, 23(1): 62-65.